These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11227398)

  • 1. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 2. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
    Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H
    Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 10. Brief review: rivastigmine, a second cholinesterase inhibitor.
    Patterson C; Hogan DB
    Can J Neurol Sci; 2001 Feb; 28 Suppl 1():S122-3. PubMed ID: 11237306
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
    Casademont J; Miró O; Rodriguez-Santiago B; Viedma P; Blesa R; Cardellach F
    J Neurol Sci; 2003 Jan; 206(1):23-6. PubMed ID: 12480080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 14. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 17. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
    Adler G; Brassen S
    Neuropsychobiology; 2001; 43(4):273-6. PubMed ID: 11340368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine in the treatment of Alzheimer's disease.
    Deleu D
    Eur Neurol; 2001; 46(2):110. PubMed ID: 11528167
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
    Alagiakrishnan K; Sclater A; Robertson D
    J Am Geriatr Soc; 2003 Sep; 51(9):1326. PubMed ID: 12919253
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.